NCT06841510Active, not recruiting
Efficacy and Safety of GENOSS SES in Patients With Coronary Artery Disease
A Prospective, Multicenter, Observational Study to Evaluate the Efficacy and Safety of GENOSS SES in Patients With Coronary Artery Disease
Source: ClinicalTrials.gov · Last updated 16 Sept 2025
Brief summary (registry, in English)
Efficacy and Safety of GENOSS SES in patients with coronary artery disease
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 1118 (actual)
- First submitted
- 17 Feb 2025
- Start date
- 19 Apr 2018
- Primary completion date
- 30 Nov 2025
- Lead sponsor
- Genoss Co., Ltd.
- Diseases
- Coronary artery disease
- NCT number
- NCT06841510
What you commit to
- Study type: Observational
- Participants enrolled: 1118
- From 19 Apr 2018 to the primary completion date, 30 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with a planned surgery to discontinue antiplatelet agents within 12 months
- Patients who have already received treatment with another DES (Drug Eluting Stent) or BMS (Bare Metal Stent) at the time of registration
Other
- Patients who are contraindicated in the use of heparin, aspirin, clopidogrel, sirolimus, cobalt chromium and contrast agents
- Patients who are pregnant or planning to become pregnant
- Patients with a life expectancy of less than 1 year
- Patient with cardiogenic shock at the time of hospitalization and had a low chance of survival based on medical judgment.
- Patients participating in randomized controlled trials using other medical devices
Who the study is looking for
- Patients of 19 and over
- Patients with coronary artery disease treated with GENOSS SES
- Participants who voluntarily decide to participate in this clinical trial, agree to the study protocol and clinical follow-up plan, and provide written informed consent as study participants
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul National University Bundang Hospital Coordinator of this site? Confirm its status | Seongnam | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.